Mild Autonomous Cortisol Secretion study: Intervention
Official title IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
ClinicalTrials.gov ID: NCT07361874
What this study is testing
What is Intervention 2: Semaglutide?
Intervention 2: Semaglutide is an investigational medicine, given as a once-weekly injection under the skin, being studied as a potential treatment for mild autonomous cortisol secretion (macs).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether surgery or a weight-loss drug works better. It also looks at how these treatments affect health and daily life.
- Who it's for
- You may be able to join if you have mild autonomous cortisol secretion.
- What's involved
- You would get either surgery or a weight-loss drug. You would also take part in health checks and tests.
- Time commitment
- The study lasts about 26 to 30 weeks with regular visits.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults ≥18 years
- MACS groups: adrenal adenoma + DST cortisol \>1.8 µg/dL + no overt Cushing + eligible for adrenalectomy
- Willingness to postpone surgery 6 months if assigned by chance
- Controls: no adrenal abnormalities + normal DST + BMI ≥27 + ≥2 cardiometabolic conditions
- Stable medication doses for ≥4 weeks
You likely can't join if
- Prior GLP-1 RA within 90 days
- Weight change \>5 kg in past 90 days
- Prior obesity/diabetes surgery
- Type 1 diabetes or other diabetes types
- Severe organ disease
- Recent pancreatitis
See the full eligibility criteria
- Adults ≥18 years
- MACS groups: adrenal adenoma + DST cortisol \>1.8 µg/dL + no overt Cushing + eligible for adrenalectomy
- Willingness to postpone surgery 6 months if assigned by chance
- Controls: no adrenal abnormalities + normal DST + BMI ≥27 + ≥2 cardiometabolic conditions
- Stable medication doses for ≥4 weeks
- Negative pregnancy test if applicable
- Prior GLP-1 RA within 90 days
- Weight change \>5 kg in past 90 days
- Prior obesity/diabetes surgery
- Type 1 diabetes or other diabetes types
- Severe organ disease
- Recent pancreatitis
- Pregnancy, breastfeeding
- Contraindication to semaglutide
- Contraindication to surgery delay
- Chronic glucocorticoid use
The study team makes the final eligibility decision.
Where it is enrolling
- Dallas, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Dallas, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.